Ngahane et al. (46) |
Cameroon |
Cross-sectional Includes HIV+
|
269 |
Structural (CXR lesions) and Functional (dyspnoea and spirometry) |
No |
Ralph et al. (13) |
Indonesia |
Longitudinal [Baseline (BL), 6M & over 6M] Includes HIV+
|
200 |
Structural (CXR score of lesions and cavitation) and Functional (dyspnoea, SGRQ, spirometry) |
No |
Kumar et al. (47) |
India |
Longitudinal (BL & 6M) No HIV+ cases Part of larger study involving patients with co-morbidities |
24 |
Structural (cavitation; no CXR-score) |
Yes |
Ravimohan et al. (48) |
USA |
Prospective (over 6M) All TB/HIV+
|
14 |
Functional (spirometry) |
Yes (MMPs) |
Pasipanodya et al. (11) |
USA |
Longitudinal (BL, 6M & over 6M) Includes HIV+
|
177 |
Functional (SGRQ and spirometry) |
No |
Plit et al. (42) |
South Africa |
Longitudinal (BL & 6M) Includes HIV+
|
76 |
Structural (CXR score of lung infiltrates) Functional (spirometry) |
Yes (c-reactive protein (CRP) and serum α1-protease inhibitor (α1-PI) |
Cole et al. (43) |
South Africa |
Cross-sectional Includes HIV+
|
55 |
Functional (SGRQ and spirometry) |
No |
Patil and Patil (44) |
India |
Longitudinal (6M, 9M, & 12M) No HIV+ cases |
118 |
Functional (dyspnoea and spirometry) |
No |
Hnizdo et al. (4) |
South Africa |
Retrospective (BL-−375M) Includes HIV+
|
2,599 |
Functional (spirometry) |
No |
Maguire et al. (45) |
Indonesia |
Longitudinal (BL, 2M, & 6M) Includes HIV+
|
115 |
Functional (dyspnoea, SGRQ, spirometry) |
No |
Saldana et al. (41) |
Mexico |
Cross-sectional Includes HIV+
|
127 |
Functional (Spirometry) and Structural (CXR abnormalities) |
No |
Vecino et al. (14) |
USA |
Longitudinal (BL, 6M, & over 6M) |
123 |
Functional (Spirometry) |
No |
Chushkin et al. (3) |
Russia |
Prospective (Over 12M) Undetermined HIV status |
214 |
Functional (Spirometry) |
No |